IP Library Granted Patent US 10,624,906
Granted Patent B1
US 10,624,906 · App. 16/682,477 · Granted Apr 21, 2020

Spironolactone aqueous compositions

Inventors: Anthony Pipho (Winterville, NC); Michael Paul DeHart (Winterville, NC)
Assignee: CMP Development LLC
A61K31/585A61K9/0053A61K9/0095A61K9/20A61K47/02A61K47/10A61K47/12A61K47/24A61K47/36A61K9/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,906
App. No.
16/682,477
Granted
Apr 21, 2020
Kind
B1
Abstract

Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.

Claims (21)

1. A ready-to-use liquid formulation, comprising:

(a) about 0.20% w/v to about 1.0% w/v of spironolactone;

(b) from about 0.18% w/v to about 0.36% w/v of a xanthan gum;

(c) a pharmaceutically acceptable excipient; and

(d) a sufficient amount of a water vehicle;

wherein the formulation has a spironolactone content of 100±10% labeled content when stored for about 24-months at 25±2° C. and 40±5% relative humidity.

2. The ready-to-use liquid formulation of claim 1 , which comprises from about 0.3% w/v to about 0.8% w/v of spironolactone.

3. The ready-to-use liquid formulation of claim 2 , which comprises from about 0.20% w/v to about 0.32% w/v of a xanthan gum.

4. An enclosed bottle comprising the ready-to-use liquid formulation of claim 3 .

5. The ready-to-use liquid formulation of claim 1 , which comprises from about 0.4% w/v to about 0.6% w/v of spironolactone.

6. The ready-to-use liquid formulation of claim 5 , which comprises from about 0.20% w/v to about 0.32% w/v of a xanthan gum.

7. An enclosed bottle comprising the ready-to-use liquid formulation of claim 6 .

8. The ready-to-use liquid formulation of claim 1 , which comprises about 0.5% w/v of spironolactone.

9. The ready-to-use liquid formulation of claim 8 , which comprises about 0.25% of a xanthan gum.

10. The ready-to-use liquid formulation of claim 9 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of an anti-foaming agent, a preservative, a dispersing agent, a sweetening agent, a flavoring agent, a buffer to maintain the pH of the formulation from 4.5 to 5.5, and a combination thereof.

11. The ready-to-use liquid formulation of claim 9 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of from 0.2% w/v to 0.6% w/v of an anti-foaming agent, from 0.125% w/v to 0.250% w/v of a preservative, from 1.8% w/v to 2.4% w/v of a dispersing agent, from 0.04% w/v to 0.6% w/v of a sweetening agent, from 0.1% w/v to 0.5% w/v of a flavoring agent, a sufficient amount of a buffer to maintain the pH of the formulation from 4.5 to 5.5, and a combination thereof.

12. The ready-to-use liquid formulation of claim 11 , wherein the buffer is selected from the group consisting of an acetate buffer, an aconitate buffer, a glutarate buffer, a glutamate buffer, a malate buffer, a succinate buffer, a tartrate buffer, a citrate buffer, and a phosphate buffer.

13. The ready-to-use liquid formulation of claim 12 , wherein the sufficient amount of buffer ranges from about 10 mM to about 100 mM.

14. An enclosed bottle comprising the ready-to-use liquid formulation of claim 9 .

15. The bottle of claim 14 , wherein the volume of said bottle is 4 oz. or 16 oz.

16. The ready-to-use liquid formulation of claim 15 , wherein a uniform content amount of spironolactone of about 100% l.c. is achieved within about 10 seconds of shaking.

Assignments (5)
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Jan 21, 2025
From: FIRST HORIZON BANK, F/K/A FIRST TENNESSEE BANK, N.A.
To: TEXAS CAPITAL BANK
Reel/Frame 069967/0622 →
SECURITY INTEREST Recorded May 18, 2022
From: CMP PHARMA, INC.; CMP ACQUISITION COMPANY LLC; CMP DEVELOPMENT LLC
To: FIRST HORIZON BANK FKA FIRST TENNESSEE BANK NATIONAL ASSOCIATION
Reel/Frame 059948/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: PIPHO, ANTHONY
To: CMP DEVELOPMENT LLC
Reel/Frame 055931/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: DEHART, MICHAEL P
To: MAYNE PHARMA, INC. DBA METRICS CONTRACT SERVICES
Reel/Frame 055931/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: MAYNE PHARMA INC., DBA METRICS CONTRACT SERVICES
To: CMP DEVELOPMENT LLC
Reel/Frame 055931/0856 →
Continuity (3)
Continuation 15665014 · Jul 31, 2017
Continuation In Part 15337559 · Oct 28, 2016
Provisional Application 62495583 · Oct 30, 2015